NASDAQ · LBRX
LB Pharmaceuticals Inc Common Stock
$40.15+$0.32 (+0.8%)
LB Pharmaceuticals Inc Common Stock’s quoted price sits in the upper half of its reported 52-week range, 19.96% below the high.
Loading market information…
NASDAQ · GALT · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Galectin Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.63% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Galectin Therapeutics Inc.’s next earnings report is currently expected on Nov 13, 2026, with estimated earnings per share of -$0.05. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Galectin Therapeutics Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysaccharide polymer. This compound is currently undergoing Phase III clinical trials, assessing its effectiveness in treating liver scarring linked to fatty liver disease and non-alcoholic steatohepatitis (NASH) cirrhosis, alongside its potential for cancer treatment. Beyond belapectin, Galectin Therapeutics is progressing GM-CT-01 through preclinical stages for the management of cardiac and vascular fibrosis. The company is also actively exploring additional uses for belapectin in conditions like psoriasis, lung fibrosis, and kidney fibrosis. Furthermore, through Galectin Sciences, LLC – a joint venture established with SBH Sciences, Inc. – the firm is involved in researching and developing small organic molecules designed to block galectin-3, intended for oral administration. Established in 2000, the company was initially known as Pro-Pharmaceuticals, Inc. before officially changing its name to Galectin Therapeutics, Inc. in May 2011. Its corporate headquarters are located in Norcross, Georgia.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 12:27 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $0.00 |
| Q4 2024 | Mar 31, 2025 | -$0.19-18.75% vs estimate | $36.00K |
|---|
| Q3 2024 | Nov 14, 2024 | -$0.18+10.0% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
11 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$40.15+$0.32 (+0.8%)
LB Pharmaceuticals Inc Common Stock’s quoted price sits in the upper half of its reported 52-week range, 19.96% below the high.
$13.23-$0.12 (-0.9%)
Alpha Tau Medical Ltd’s quoted price sits in the upper half of its reported 52-week range, 16.21% below the high.
$11.06-$0.02 (-0.18%)
Design Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 35.88% below the high.
$6.30-$0.11 (-1.64%)
Aura Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.01% below the high.
$2.88-$0.02 (-0.69%)
I-Mab’s quoted price sits in the lower half of its reported 52-week range, 57.58% below the high.
$9.52-$0.30 (-3.05%)
DiaMedica Therapeutics Inc.’s quoted price sits in the upper half of its reported 52-week range, 8.64% below the high.
$2.14+$0.04 (+1.9%)
Altimmune, Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.77% below the high.
$1.75+$0.03 (+1.74%)
Quantum-Si incorporated’s quoted price sits in the upper half of its reported 52-week range, 20.09% below the high.
